Zhengye Biotechnology Receives Nasdaq Delisting Warning for Sub-$1.00 Stock Price
ZYBT sits 22% above its 52-week low of $0.68.
Summary
Zhengye Biotechnology received a Nasdaq notice for failing to meet the minimum bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.
Key Events · Corporate Governance and Compliance · ZYBT
-
Nasdaq Minimum Bid Price Deficiency
The company received a formal notice from Nasdaq on May 29, 2026, for failing to maintain a minimum bid price of $1.00 for 30 consecutive business days.
-
180-Day Compliance Period
Zhengye Biotechnology has until November 25, 2026, to regain compliance by having its Class A ordinary shares close at or above $1.00 for at least 10 consecutive business days.
-
Potential Reverse Stock Split
The company is considering implementing a reverse stock split, a measure previously approved by shareholders on March 24, 2026, to cure the bid price deficiency.
-
Financial Performance Context
This delisting warning follows the company's recent 20-F filing on April 28, 2026, which reported a substantial net loss and significant revenue decline for fiscal year 2025.
Analysis · ZYBT · Life Sciences
Zhengye Biotechnology has received a formal notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. This triggers a 180-day compliance period, ending November 25, 2026, to regain compliance or face potential delisting. The company's stock has been trading below $1.00, a situation exacerbated by its recent reporting of substantial net losses and revenue decline in its fiscal year 2025 20-F filing. While the company previously secured shareholder approval for a reverse stock split in March 2026, this formal notice from Nasdaq intensifies the pressure to execute such a measure to maintain its listing.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.7% of the 1024 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZYBT was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.7M. The 52-week trading range was $0.68 to $13.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.